Literature DB >> 29574080

Dose- and time-dependent pharmacokinetics of apigenin trimethyl ether.

Mai Gamal Elhennawy1, Hai-Shu Lin2.   

Abstract

Apigenin trimethyl ether (5,7,4'-trimethoxyflavone, ATE), one of the key polymethoxyflavones present in black ginger (rhizome of Kaempferia parviflora) possesses various health-promoting activities. To optimize its medicinal application, the pharmacokinetics of ATE was assessed in Sprague-Dawley rats with emphases to identify the impacts from dose and repeated dosing on its major pharmacokinetic parameters. Plasma ATE levels were monitored by liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Upon single intravenous administration (2 mg/kg), plasma levels of ATE declined through an apparent first-order process while dose-escalation to 4 and 8 mg/kg led to its non-linear disposition, which could be described by the Michaelis-Menten model. Similarly, dose-dependent oral pharmacokinetics was confirmed and when the dose was escalated from 5 to 15 and 45 mg/kg, much longer mean residence time (MRT0→last), higher dose-normalized maximal plasma concentration (Cmax/Dose) and exposure (AUC/Dose) were observed at 15 and/or 45 mg/kg. One-week daily oral administration of ATE at 15 mg/kg caused its accelerated elimination and the plasma exposure (AUC) after intravenous (2 mg/kg) and oral administration (15 mg/kg) dropped ~40 and 60%, respectively. As ATE displayed both dose- and time-dependent pharmacokinetics, caution is needed in the medicinal applications of ATE and/or black ginger.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5,7,4′-Trimethoxyflavone; Apigenin trimethyl ether; Dose-dependent pharmacokinetics; Time-dependent pharmacokinetics

Mesh:

Substances:

Year:  2018        PMID: 29574080     DOI: 10.1016/j.ejps.2018.03.022

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  6 in total

1.  Formulation of Apigenin-Cyclodextrin-Chitosan Ternary Complex: Physicochemical Characterization, In Vitro and In Vivo Studies.

Authors:  Mohammed Jafar; Mohammed Saifuddin Khalid; Hajer Alghamdi; Mohd Amir; Sarah Aon Al Makki; Ohud Saud Alotaibi; Afnan Ali Al Rmais; Syed Sarim Imam; Sultan Alshehri; Sadaf Jamal Gilani
Journal:  AAPS PharmSciTech       Date:  2022-02-10       Impact factor: 3.246

2.  Oral Administration of Isovitexin, a Naturally Occurring Apigenin Derivative Showed Osteoanabolic Effect in Ovariectomized Mice: A Comparative Study with Teriparatide.

Authors:  Subhashis Pal; Shivani Sharma; Konica Porwal; Mohammed Riyazuddin; Chirag Kulkarni; Sourav Chattopadhyay; Sabyasachi Sanyal; Jiaur R Gayen; Naibedya Chattopadhyay
Journal:  Calcif Tissue Int       Date:  2022-04-22       Impact factor: 4.000

3.  In Silico Screening and Validation of PDGFRA Inhibitors Enhancing Radioiodine Sensitivity in Thyroid Cancer.

Authors:  Xuefei Yu; Xuhang Zhu; Lizhuo Zhang; Jiang-Jiang Qin; Chunlai Feng; Qinglin Li
Journal:  Front Pharmacol       Date:  2022-05-12       Impact factor: 5.988

4.  Dissolution and bioavailability improvement of bioactive apigenin using solid dispersions prepared by different techniques.

Authors:  Sultan M Alshehri; Faiyaz Shakeel; Mohamed A Ibrahim; Ehab M Elzayat; Mohammad Altamimi; Kazi Mohsin; Osaid T Almeanazel; Musaed Alkholief; Abdullah Alshetaili; Bader Alsulays; Fars K Alanazi; Ibrahim A Alsarra
Journal:  Saudi Pharm J       Date:  2018-11-14       Impact factor: 4.330

5.  Artemether-Loaded Zein Nanoparticles: An Innovative Intravenous Dosage Form for the Management of Severe Malaria.

Authors:  Yaa Boateng-Marfo; Yuancai Dong; Wai Kiong Ng; Hai-Shu Lin
Journal:  Int J Mol Sci       Date:  2021-01-24       Impact factor: 5.923

6.  Bioactive Apigenin loaded oral nano bilosomes: Formulation optimization to preclinical assessment.

Authors:  Ameeduzzafar Zafar; Nabil K Alruwaili; Syed Sarim Imam; Nasser Hadal Alotaibi; Khalid Saad Alharbi; Muhammad Afzal; Raisuddin Ali; Sultan Alshehri; Sami I Alzarea; Mohammed Elmowafy; Nabil A Alhakamy; Mohamed F Ibrahim
Journal:  Saudi Pharm J       Date:  2021-02-22       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.